MedTrace Logo

A Safety Study Using Pentamidine in Patients With Pancreatic Cancer Undergoing Standard Therapy

NCT00810953 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2011-06-28

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety and possible efficacy of the use of pentamidine in the treatment of pancreatic cancer metastasis in subjects receiving standard therapy.

Conditions

Interventions

DRUG

Pentamidine

two dose of 6 mg/kg with or without standard chemotherapy.

Sponsors & Collaborators

  • Oncozyme Pharma Inc.

    lead INDUSTRY

Principal Investigators

  • Petr Kavan, MD, Ph.D. · McGill University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2010-06-30
Completion
2011-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00810953 on ClinicalTrials.gov